The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of ViroPharma's 2013 immunology sales performance.
The Viropharma deal - which closed last month - brings in an already-marketed drug for hereditary angioedema with sales running at around $100m a quarter last year. ... After a strong performance in 2013, and the completion of the ViroPharma acquisition,
This includes a restructure of its pipeline, as announced in November last year, as well as the £2bn purchase of rare disease specialist ViroPharma.
acquisitions. Following the rumours that had abounded over the last few months, the top of the table deal this month was the acquisition of ViroPharma, the orphan drugs company by Shire. ... In 2012 ViroPharma generated revenues of $428m, with Cinryze
Gains access to Cinryze in expensive but 'strategically sound' deal. Shire has signed a deal to buy US company ViroPharma for around $4.2bn as it continues to build its portfolio ... The $50-per-share cash offer has been approved by both companies' board
Alexion, Biomarin and ViroPharma have all been under the spotlight this month as speculation shifts from large Pharma looking to get in on the action or an existing niche player making
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...